Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 1, 2010, Pages 69-78

  Schoedel, K A ^a   Meier, D ^b   Chakraborty, B ^a   Manniche, P M ^b   Sellers, E M ^a,c,d  

^a Kendle Early Stage   (Canada)

^b NEUROSEARCH A S   (Denmark)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; DEXAMPHETAMINE; PLACEBO; TESOFENSINE; TRIPLE REUPTAKE INHIBITOR;

ADULT; AGITATION; ALERTNESS; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; EUPHORIA; FEMALE; HEADACHE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE TIGHTNESS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TACHYCARDIA; URINE RETENTION; VISUAL ANALOG SCALE; VITAL SIGN; XEROSTOMIA;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; ATTENTION; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOGENIC MONOAMINES; BUPROPION; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DEXTROAMPHETAMINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PROPYLAMINES; PSYCHOMOTOR PERFORMANCE; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953812675     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.67     Document Type: Article

References (45)

1. Hauser, R.A., Salin, L., juhel, N. & Konyago, V.L. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov. Disord. 22, 359-365 (2007).
2. Rascol, O. et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fuctuations: the ADVANS Study. Arch. Neurol. 65, 577-583 (2008).
3. Astrup, A., Meier, D.H., Mikkelsen, B.O., Villumsen, J.S. & Larsen, T.M. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring). 16, 1363-1369 (2008).
4. Astrup, A., Madsbad, S., Breum, L., jensen, T.J., Kroustrup, J.P. & Larsen, T.M. Efect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372, 1906-1913 (2008).
5. Rowley, H.L. et al. Comparison of the efects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse 38, 167-176 (2000)
6. jasinski, D.R., Faries, D.E., Moore, R.J., Schuh, L.M. & Allen, A.J. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend. 95, 140-146 (2008).
7. Cole, J.O., Levin, A., Beake, B., Kaiser, P.E. & Scheinbaum, M.L. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J. Clin. Psychopharmacol. 18, 231-236 (1998).
8. Schuh, L.M., Schuster, C.R., Hopper, J.A. & Mendel, C.M. Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology (Berl.) 147, 339-346 (2000).
9. Arfken, C.L. & Cicero, T.J. Postmarketing surveillance for drug abuse. Drug Alcohol Depend. 70, S97-S105 (2003).
10. Arfken, C.L., Schuster, C.R. & johanson, C.E. Postmarketing surveillance of abuse liability of sibutramine. Drug Alcohol Depend. 69, 169-173 (2003).
11. Busto, U. & Sellers, E.M. Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective. Clin. Pharmacokinet. 11, 144-153 (1986).
12. Farré, M. & Camí, J. Pharmacokinetic considerations in abuse liability evaluation. Br. J. Addict. 86, 1601-1606 (1991).
13. Swanson, J.M. & Volkow, N.D. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci. Biobehav. Rev. 27, 615-621 (2003).
14. Volkow, N.D. et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry 52, 456-463 (1995).
15. Volkow, N.D. & Swanson, J.M. Variables that afect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am. J. Psychiatry 160, 1909-1918 (2003).
16. Abreu, M.E., Bigelow, G.E., Fleisher, L. & Walsh, S.L. Efect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl.) 154, 76-84 (2001).
17. Ferrario, C.R., Shou, M., Samaha, A.N., Watson, C.J., Kennedy, R.T. & Robinson, T.E. The rate of intravenous cocaine administration alters c-fos mRNA expression and the temporal dynamics of dopamine, but not glutamate, overfow in the striatum. Brain Res. 1209, 151-156 (2008).
18. Kollins, S.H., Rush, C.R., Pazzaglia, P.J. & Ali, J.A. Comparison of acute behavioral efects of sustained-release and immediate-release methylphenidate. Exp. Clin. Psychopharmacol. 6, 367-374 (1998).
19. Samaha, A.N., Mallet, N., Ferguson, S.M., Gonon, F. & Robinson, T.E. The rate of cocaine administration alters gene regulation and behavioral plasticity: implications for addiction. J. Neurosci. 24, 6362-6370 (2004).
20. Samaha, A.N., yau, W.y., yang, P. & Robinson, T.E. Rapid delivery of nicotine promotes behavioral sensitization and alters its neurobiological impact. Biol. Psychiatry 57, 351-360 (2005).
21. Samaha, A.N. & Robinson, T.E. Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol. Sci. 26, 82-87 (2005).
22. Parasrampuria, D.A. et al. Assessment of pharmacokinetics and pharmacodynamic efects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J. Clin. Pharmacol. 47, 1476-1488 (2007).
23. Parasrampuria, D.A. et al. Do formulation diferences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J. Clin. Psychopharmacol. 27, 459-467 (2007).
24. Spencer, T.J. et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short-and long-acting oral methylphenidate. Am. J. Psychiatry 163, 387-395 (2006).
25. Volkow, N.D., Fowler, J.S., Wang, G., Ding, y. & Gatley, S.J. Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord. 6 (suppl. 1), S31-S43 (2002).
26. Volkow, N.D. Stimulant medications: how to minimize their reinforcing efects? Am. J. Psychiatry 163, 359-361 (2006).
27. Volkow, N.D., Fowler, J.S., Wang, G.J., Ding, y.S. & Gatley, S.J. Role of dopamine in the therapeutic and reinforcing efects of methylphenidate in humans: results from imaging studies. Eur. Neuropsychopharmacol. 12, 557-566 (2002).
28. Grifth, J.D., Carranza, J., Grifth, C. & Miller, L.L. Bupropion: clinical assay for amphetamine-like abuse potential. J. Clin. Psychiatry 44, 206-208 (1983).
29. Heishman, S.J. & Henningfeld, J.E. Discriminative stimulus efects of d-amphetamine, methylphenidate, and diazepam in humans. Psychopharmacology (Berl.) 103, 436-442 (1991).
30. Miller, L. & Grifth, J. A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology (Berl.) 80, 199-205 (1983).
31. Stoops, W.W., Glaser, P.E., Fillmore, M.T. & Rush, C.R. Reinforcing, subject-rated, performance and physiological efects of methylphenidate and d-amphetamine in stimulant abusing humans. J. Psychopharmacol. (Oxford) 18, 534-543 (2004).
32. Milovan, D., Schoedel, K.A., Romach, M.K. & Sellers, E.M. Clinically Relevant Efects of Abused Drugs in Human Abuse Potential Studies Based on Subjective Response Patterns. College on Problems of Drug Dependence 71st Annual Meeting, june 20-25, Reno/Sparks, NV, 2009.
33. Guidance Document: Clinical Assessment of Abuse Liability for Drugs with Central Nervous System Activity. Therapeutic Products Directorate, Health Canada (2007).
34. Balster, R.L. & Bigelow, G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 70, S13-S40 (2003).
35. Grifths, R.R., Bigelow, G.E. & Ator, N.A. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 70, S41-S54 (2003).
36. McColl, S. & Sellers, E.M. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend. 83 (suppl. 1), S52-S62 (2006).
37. Schoedel, K.A. & Sellers, E.M. Assessing abuse liability during drug development: changing standards and expectations. Clin. Pharmacol. Ther. 83, 622-626 (2008)
38. Report of the United Nations International Narcotics Control Board for 2006. United Nations Publication (2006).
39. Setlik, J., Bond, G.R. & Ho, M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics (2009); e-pub ahead of print 24 August 2009.
40. Substance Abuse and Mental Health Services Administration, Ofce of Applied Studies. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits. DHHS Publication No. (SMA) 08-4339. 2008. Rockville, MD, DAWN Series D-30 (2008).
41. McColl, S.L., Burstein, A.H., Reeves, K.R., Billing, C.B. jr, Stolar, M. & Sellers, E.M. Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. Clin. Pharmacol. Ther. 83, 607-614 (2008).
42. Martin, W.R., Sloan, J.W., Sapira, J.D. & jasinski, D.R. Physiologic, subjective, and behavioral efects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 12, 245-258 (1971).
43. Haertzen, C. An Overview of the Addiction Research Center Inventory (ARCI): An Appendix and Manual of Scales. National Institute on Drug Abuse: Rockville, MD (1974).
44. Grifths, R.R., Rush, C.R, & Puhala, K.A. Validation of the multiple-choice procedure for investigating drug reinforcement in humans. Exp. Clin. Psychopharmacol. 4, 97-106 (1996).
45. Kaplan, H.L. When do professional psychologists need professional programmers' tools? Behav. Res. Methods Instrum. Comput. 17, 546-550 (1985).